Konstanze Döhner

Active 1998–2025

192
Papers
47,510
Citations
105
h-index
186
i10-index

Citations

Citations per year for Konstanze Döhner1984: 2 citations1999: 7 citations2000: 13 citations2001: 17 citations2002: 52 citations2003: 54 citations2004: 69 citations2005: 169 citations2006: 215 citations2007: 218 citations2008: 283 citations2009: 293 citations2010: 335 citations2011: 389 citations2012: 395 citations2013: 388 citations2014: 464 citations2015: 433 citations2016: 487 citations2017: 515 citations2018: 446 citations2019: 1,802 citations2020: 1,909 citations2021: 1,691 citations2022: 1,307 citations2023: 1,092 citations2024: 1,455 citations2025: 623 citations2026: 11 citations1985–1998: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,513 citing papers, 26.8% of this breakdownGermany: 1,673 citing papers, 9.9% of this breakdownChina: 1,280 citing papers, 7.6% of this breakdownUnited Kingdom: 1,185 citing papers, 7% of this breakdownItaly: 1,005 citing papers, 6% of this breakdownFrance: 804 citing papers, 4.8% of this breakdownSpain: 557 citing papers, 3.3% of this breakdownNetherlands: 522 citing papers, 3.1% of this breakdownCanada: 508 citing papers, 3% of this breakdownJapan: 392 citing papers, 2.3% of this breakdownSwitzerland: 386 citing papers, 2.3% of this breakdownAustralia: 382 citing papers, 2.3% of this breakdown
0%26.8%Other 21.6%

Fields

  • Medicine67.6%
  • Biochemistry, Genetics and Molecular Biology28.5%
  • Immunology and Microbiology2.1%
  • Computer Science0.6%
  • Chemistry0.2%
  • Mathematics0.2%
  • Other0.8%

Topics

  • Acute Myeloid Leukemia Research16.6%
  • Myeloproliferative Neoplasms: Diagnosis and Treatment5.9%
  • Chronic Myeloid Leukemia Treatments4.1%
  • Cancer Genomics and Diagnostics3.6%
  • Chronic Lymphocytic Leukemia Research3.5%
  • Epigenetics and DNA Methylation3.5%
  • Other62.8%

Coauthors

All papers

Open in search
  1. Genomic Classification and Prognosis in Acute Myeloid Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2016 cited by 4,363

  2. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2017 cited by 2,198

  3. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Farhad Ravandi, Christophe Roumier, Marion Subklewe, Felicitas Thol, Arjan A. van de Loosdrecht, Bert A. van der Reijden, Adriano Venditti, Agnieszka Wierzbowska, Peter J.M. Valk, Brent L. Wood, Roland B. Walter, Christian Thiede, Konstanze Döhner, Gail J. Roboz, Jacqueline Cloos - Blood 2021 cited by 718

  4. Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hartmut Link, Maria Grazia Kropp, Alessandro Rambaldi, Giorgio La Nasa, Mario Luppi, Fabio Ciceri, Olimpia Finizio, Adriano Venditti, Francesco Fabbiano, Konstanze Döhner, Michaela Sauer, Arnold Ganser, Sergio Amadori, Franco Mandelli, Hartmut Döhner, Gerhard Ehninger, Richard F. Schlenk, Uwe Platzbecker - New England Journal of Medicine 2013 cited by 1,606

  5. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Blood 2018 cited by 1,029

  6. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2005 cited by 2,991

  7. Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia

    Authors: , , , , , , , , - New England Journal of Medicine 2000 cited by 3,296

  8. Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia

    Authors: , , , , , , , , , , , , , - Science 2020 cited by 271

  9. Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Cindy Zhang, Rinnat M. Porat, Diana M. Merino, Jonathan D. Wasserman, Nada Jabado, Adam M. Fontebasso, Lars Bullinger, Frank G. Rücker, Konstanze Döhner, Hartmut Döhner, Jan Köster, Jan J. Molenaar, Rogier Versteeg, Marcel Kool, Uri Tabori, David Malkin, Andrey Korshunov, Michael D. Taylor, Peter Lichter, Stefan M. Pfister, Jan O. Korbel - Cell 2012 cited by 878

  10. Unified classification and risk-stratification in Acute Myeloid Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2022 cited by 175

  11. SEURAT: Visual analytics for the integrated analysis of microarray data

    Authors: , , , , , , , - BMC Medical Genomics 2010 cited by 257

  12. A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , - Cell 2014 cited by 720

  13. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome

    Authors: , , , , , , , , , , , , , , , , , , , , , - Blood 2011 cited by 678

  14. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hartmut Döhner, Arnold Ganser, Michael Heuser - Blood 2018 cited by 301

  15. Genomics of Acute Myeloid Leukemia Diagnosis and Pathways

    Authors: , , - Journal of Clinical Oncology 2017 cited by 585

  16. Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2021 cited by 158

  17. Effect of Mutation Order on Myeloproliferative Neoplasms

    Authors: , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2015 cited by 575

  18. Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ross L. Levine, Ari Melnick, Christopher E. Mason - Nature Medicine 2016 cited by 401

  19. Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood Advances 2021 cited by 119

  20. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sergio Amadori, Insa Gathmann, Axel Benner, Céline Pallaud, Richard M. Stone, Hartmut Döhner, Clara D. Bloomfield - Blood 2019 cited by 193

  21. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09–09): a randomised, open-label, multicentre, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Peter Paschka, Verena I. Gaidzik, Maral Saadati, Axel Benner, Richard F. Schlenk, Konstanze Döhner, Arnold Ganser, Hartmut Döhner, Daniela Weber, Julia Krzykalla, Walter Fiedler, Michael W.M. Kühn, Thomas Schroeder, Karin Mayer, Michael Lübbert, Mohammad Amen Wattad, Katharina S. Götze, Lars Fransecky, Elisabeth Koller, Gerald Wulf, Jan Schleicher, Mark Ringhoffer, Richard Greil, Bernd Hertenstein, Jürgen Krauter, Uwe M. Martens, David Nachbaur, Maisun Abu Samra, Sigrid Machherndl-Spandl, Nadezda Basara, Claudia Leis, Anika Schrade, Silke Kapp‐Schwoerer, Sibylle Cocciardi, Lars Bullinger, Felicitas Thol, Michael Heuser, Peter Paschka, Verena I. Gaidzik, Maral Saadati, Axel Benner, Richard F. Schlenk, Konstanze Döhner, Arnold Ganser - The Lancet Haematology 2023 cited by 57

  22. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michael Hallek, Hartmut Döhner - Blood 2014 cited by 507

  23. Monitoring of Minimal Residual Disease in NPM1 -Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2011 cited by 394

  24. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Chiara Frairia, Enrico Maria Pogliani, Claudio Fozza, Alfonso Maria D’Arco, Nicola Di Renzo, Agostino Cortelezzi, Francesco Fabbiano, Konstanze Döhner, Arnold Ganser, Hartmut Döhner, Sergio Amadori, Franco Mandelli, Gerhard Ehninger, Richard F. Schlenk, Francesco Lo‐Coco - Journal of Clinical Oncology 2016 cited by 392